Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man

British Journal of Clinical Pharmacology

Volumn 45, Issue 4, 1998, Pages 355-359

  Kupferschmidt, Hugo H T ^a   Fattinger, Karin E ^a   Ha, Huy Riem ^a   Follath, Ferenc ^a   Krähenbühl, Stephan ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Bioavailability; CYP3A4; Grapefruit juice; HIV; Interaction; Pharmacokinetics; Protease inhibitor; Saqumavir

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CYTOCHROME P450; PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CITRUS FRUIT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL; VIRUS INFECTION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BEVERAGES; BIOLOGICAL AVAILABILITY; CITRUS; CYTOCHROME P-450 ENZYME SYSTEM; FOOD-DRUG INTERACTIONS; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIXED FUNCTION OXYGENASES; SAQUINAVIR;

EID: 0031908050     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00687.x     Document Type: Article

References (28)

1. Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993; 328: 1686-1695.
2. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-4690.
3. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Prof Natl Acad Sci USA 1990; 87: 7472-7476.
4. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248: 358-361.
5. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-955.
6. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infectcd patients. Ann Intern Med 1996; 124: 1039-1050.
7. Noble S, Faulds D, Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52: 93-112.
8. Farrar G, Mitchell AM, Hooper H, Stewart F, Malcolm SL. Prediction of potential drug interactions of saquinavir (Ro 31-8959) from in vitro data. Br J Clin Pharmacol 1994; 38: 162P.
9. De Waziers I, Cugenenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253: 387-394.
10. Kivistö KT, Bookjans G, Fromm MF, Griese EU, Münzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996; 42: 387-389.
11. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995; 40: 270-272.
12. Aranko K, Luurila H, Backmann JT, Neuvonen PJ, Olkkola KT. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zoplicone. Br J Clin Pharmacol 1994; 38: 363-367.
13. Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD. Erythromycine felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996; 60: 25-33.
14. Edwards DJ, Bernier SM. Naringin and nanngenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996; 59: 1025-1030.
15. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993; 53: 637-642.
16. Edwards DJ, Bellevue FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996; 24: 1287-1290.
17. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosprin concentration. Lancet 1995; 345: 955-956.
18. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-269.
19. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-28.
20. Ha HR, Follath F, Bloemhard Y, Krähenbühl S. Determination of saquinavir in human plasma by high-performance liquid chromatography. J Chromatogr B 1997; 694: 427-433.
21. Pirttiaho HI, Sotaniemi EA, Pelkonen RO, Pitkänen U. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol 1982; 22: 441-445.
22. Dixon WJ, Mood AM. The statistical sign test. J Am Statist Assoc 1946; 41: 557-566.
23. Muirhead GJ, Shaw T, Williams PEO, Madigan MJ, Mitchell AM, Houston AC. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 318959, after single and multiple oral doses in healthy volunteers. Br J Clin Pharmacol 1992; 34: 170P-171P.
24. Williams PEO, Muirhead GJ, Madigan MJ, Mitchell AM, Shaw T. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro31-8959, after single doses in healthy volunteers. Br J Clin Pharmacol 1992; 34: 155P-156P.
25. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosponne. Clin Pharmacol Ther 1995; 58: 492-497.
26. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
27. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-431.
28. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29-F33.